Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr 30:8:985-90.
doi: 10.2147/OTT.S78836. eCollection 2015.

Impact of beta-blockers on prostate cancer mortality: a meta-analysis of 16,825 patients

Hua Lu  1 , Xingjie Liu  2 , Fengfu Guo  2 , Shanfeng Tan  2 , Guangjian Wang  2 , Hongjun Liu  2 , Jianming Wang  2 , Xiangfei He  2 , Yanshuai Mo  2 , Benkang Shi  3
Affiliations

Impact of beta-blockers on prostate cancer mortality: a meta-analysis of 16,825 patients

Hua Lu et al. Onco Targets Ther. .

Abstract

Introduction: Increasing evidence suggests that beta-blocker use might be associated with reduced mortality in prostate cancer patients. To provide a quantitative assessment of this association, we pooled data available to examine the association between beta-blocker use and mortality of prostate cancer.

Methods: We identified studies by a literature search of MEDLINE (from 1 January 1966) and EMBASE (from 1 January 1974), through 10 September 2014, and by searching the reference lists of pertinent articles. Two authors independently screened and reviewed the eligibility of each study. The primary outcomes were prostate cancer-specific mortality and all-cause mortality.

Results: A total of four studies including 16,825 patients were included in this meta-analysis. Analysis of all studies showed that beta-blocker use was associated with reduced prostate cancer-specific mortality (hazard ratio =0.85, 95% confidence interval =0.77-0.94), without any heterogeneity between studies (Q=3.59, I2=16.5%, P=0.309). However, we observed no association with all-cause mortality (hazard ratio =0.97, 95% confidence interval =0.90-1.04). There was also no evidence of the presence of significant heterogeneity between the four studies (Q=2.48, I2=0.0%, P=0.480).

Conclusion: These findings indicate that beta-blocker use was associated with reduced cancer-specific mortality among prostate cancer patients taking beta-blockers.

Keywords: beta-blocker; meta-analysis; mortality; prostate cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart on the article selection process.
Figure 2
Figure 2
Forest plot of prostate cancer-specific mortality associated with beta-blockers. Note: 0.24 to 4.17 reflects the maximal range of Hazard ratio.
Figure 3
Figure 3
Forest plot of prostate cancer all-cause mortality associated with beta-blockers. Note: 0.56 to 1.78 reflects the maximal range of Hazard ratio.
See this image and copyright information in PMC

References

    1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29. - PubMed
    1. Han S, Zhang S, Chen W, et al. Analysis of the status and trends of prostate cancer incidence in China. Chin Clin Oncol. 2013;(04):330–334. Chinese.
    1. Han S, Zhang S, Chen W, et al. Analysis of the status and trends of prostate cancer mortality in China. Chin J Urol. 2012;33(11):836–839. Chinese.
    1. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014;65(1):124–137. - PubMed
    1. Cole SW, Sood AK. Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res. 2012;18(5):1201–1206. - PMC - PubMed